TG Therapeutics Announces Publication of Five-Year Comparative Analysis of BRIUMVI Versus Ocrelizumab and Ofatumumab in Relapsing Multiple Sclerosis
TG Therapeutics announced publication in Multiple Sclerosis and Related Disorders of a five-year matching-adjusted indirect comparison showing BRIUMVI with lower relapse activity and lower risk of 24-week confirmed disability progression versus ocrelizumab and ofatumumab. In the analysis of 545 BRIUMVI-treated ULTIMATE I/II patients, the relative hazard of CDP24 was 44% lower versus ocrelizumab (HR 0.560) and 49% lower versus ofatumumab (HR 0.509), with annualized relapse rates falling to 0.030-0.032 by Year 5.
Key figures
- Drug Name
- BRIUMVI (ublituximab-xiiy)
- Phase Of Trial
- Phase 3
- Arr year5 vs ofatumumab
- 0.03
- Arr year5 vs ocrelizumab
- 0.032
- Cdp24 rate 240wk briumvi
- 9.3%
- Briumvi patients analyzed
- 545
- Ultimate trials enrollment
- 1094
- Cdp24 rate 240wk ofatumumab
- 17.9%
- Cdp24 rate 240wk ocrelizumab
- 16.1%
- Cdp24 hazard ratio vs ofatumumab
- HR 0.509
- Cdp24 hazard ratio vs ocrelizumab
- HR 0.560
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.